Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 6, 2017
Previous Article Next Article

Ring-opened aminothienopyridazines as novel tau aggregation inhibitors

Author affiliations


Aminothienopyridazines (ATPZs) have demonstrated efficacy, in vitro, as tau protein aggregation inhibitors. Modifications were made to the ATPZ scaffold to determine the importance of certain structural features for activity. More specifically, ring-opened analogues detached at the nitrogen–nitrogen bond of the pyridazine, were synthesized and their inhibitory activity evaluated. Preliminary data suggests that the ring-opened structures retain inhibitory activity, independent of tau oxidation. The structures detailed represent the beginnings of a deconstruction–reconstruction–elaboration study, with the aim of identifying simpler scaffolds, which retain activity and can be optimized in terms of physiochemical properties.

Graphical abstract: Ring-opened aminothienopyridazines as novel tau aggregation inhibitors

Back to tab navigation

Supplementary files

Publication details

The article was received on 02 Jun 2016, accepted on 03 May 2017 and first published on 05 May 2017

Article type: Research Article
DOI: 10.1039/C6MD00306K
Med. Chem. Commun., 2017,8, 1275-1282

  •   Request permissions

    Ring-opened aminothienopyridazines as novel tau aggregation inhibitors

    M. Moir, S. W. Chua, T. Reekie, A. D. Martin, A. Ittner, L. M. Ittner and M. Kassiou, Med. Chem. Commun., 2017, 8, 1275
    DOI: 10.1039/C6MD00306K

Search articles by author